Infectious Disease

Pfenex is leveraging Pfēnex Expression Technology^TM to build a comprehensive portfolio of antigens that have been difficult or impossible to express in other host systems or organisms. Capitalizing on the unprecedented ability of Pfenex to rapidly identify production strains for proteins that cannot be expressed in other systems, Pfenex enables infectious disease research and vaccine development previously not possible.

Pfenex is the first and only company able to produce full length Circumsporozoite protein (CSP), a malaria antigen.